# BPC-157 + KPV blend

Source: https://aminodesk.com/library/bpc-157-kpv
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

This blend puts BPC-157 and KPV in one vial. It is sold for gut and tissue repair with an anti-inflammatory angle. No trial has tested the combination in people, and a mixed vial falls outside the 2026 compounding policy even though each ingredient alone is covered.

- **Legal lane:** outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved.
- **Evidence grade:** D for the combination
- **What is in it:** BPC-157 and KPV
- **Established human dose:** none

## What it is

A premixed vial sold by peptide suppliers and some clinics. The ingredients:

- **[BPC-157](https://aminodesk.com/library/bpc-157):** one of the six peptides in the October 2026 policy; almost all of its evidence is from animals.
- **[KPV](https://aminodesk.com/library/kpv):** one of the six peptides in the October 2026 policy; graded D on its own page.

## What the evidence shows

There is no trial of this blend. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown.

The case for mixing them is that they act by different routes, so the effects should add up. That is a hypothesis. Nobody has measured whether the mixture does better than its parts, or whether it is as safe.

## Legal status

In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it.

Both ingredients here are on the list. A clinician can prescribe them as two separate vials within the policy. The premixed vial is outside it.

## Reported dosing

**No dose has been established for this blend.**

No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.

## Safety

- If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it.
- The ratio is fixed by the seller. You cannot adjust one ingredient without moving the others.
- No safety or absorption work exists on the mixture.
- A product made outside the pharmacy system has no verified contents or sterility.

## Common questions

### What is in this blend?

BPC-157 and KPV, mixed in one vial.

### Has this blend been tested in people?

No. There is no human trial of the combination.

### Is this blend legal?

Not as a mixed vial. Each ingredient can be compounded alone on prescription under the October 2026 policy.

## Sources

- [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf)
- [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/)

The repair blends are compared on [blends and stacks](https://aminodesk.com/stacks).

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
